echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Zhuhai put forward the goal of developing the biopharmaceutical industry in 2035: the output value will reach 120 billion yuan

    Zhuhai put forward the goal of developing the biopharmaceutical industry in 2035: the output value will reach 120 billion yuan

    • Last Update: 2020-11-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Recently, Zhuhai Municipal Bureau of Industry and Information Technology issued and implemented the Action Plan for the Promotion of High-Quality Development of the Biopharmaceutical Industry in Zhuhai City (2020-2025) (hereinafter referred to as the Action Plan) and the Measures for the Development of the Biopharmaceutical Industry in Zhuhai City (hereafter referred to as "Several Measures"), with the aim of further building a cluster of 100 billion biopharmaceutical industries.
    among them, the Action Plan defines the three stages of the development of the biopharmaceutical industry in the city, namely, the total output value of the biopharmaceutical industry will reach 26 billion yuan by 2020, more than 3 enterprises with a scale of more than 5 billion yuan, and 3 drugs will be successfully developed and listed each year; More than 6, the annual successful development of 5 listed drugs, by 2035, the total output value of the biopharmaceutical industry reached 120 billion yuan, the scale of more than 5 billion yuan enterprises more than 10, more than 10 billion yuan enterprises 2, the annual successful development of 10 listed drugs, the formation of the domestic influential biopharmaceutical science and technology innovation cluster and biopharmaceutical industry cluster development highland.
    At the same time, the Action Plan proposes six key areas of development, namely, chemicals, biological medicine, modern Chinese medicine, high-end preparations, medium and high-end medical devices, "medical care" and other fields of health, and actively promotes five key projects, namely, promoting the high-quality development of the biopharmaceutical industry through the implementation of five major projects, namely, innovation capacity improvement, industrial competitiveness promotion, industrial cluster development, high-level open cooperation, and factor support.
    measures, which are supported by the Programme of Action, propose targeted measures to address the difficulties of the development of the biopharmaceutical industry.
    , for example, for the introduction of biopharmaceutical enterprises, landing, research and development, industrialization and other stages of the characteristics and needs, to give targeted support.
    indication includes the introduction of enterprise landing stage, to give the project settlement and increase capital to expand production award support, up to 100 million yuan, in the project research and development phase, research and development support for new drugs, up to 20 million yuan, high to high-end medical device research and development support, up to 10 million yuan, up to 10 million yuan for generic drug consistency evaluation support, up to 10 million yuan in the project industrialization stage, can be up to 20 million yuan support.
    in view of the long research and development cycle of new drugs, research and development investment characteristics, "a number of measures" to introduce relevant policy support, from pre-clinical intervention, continue to support the full cycle of new drug research and development.
    If in the clinical trial stage, for entering the phase I, II, III clinical trial stage, a one-time reward of up to 3 million yuan, 5 million yuan and 10 million yuan;
    forward the nodes that support research and development innovation.
    addition, in response to the professional needs of the development of the biopharmaceutical industry, Zhuhai City from the biopharmaceutical industry public service platform, the construction of professional parks, independent innovation product promotion, export credit premium subsidies, customs clearance facilitation and other aspects of policy support.
    For example, in view of the shortage of clinical research resources in Zhuhai City, clinical research institutions with more than 5 clinical trials of new drugs and innovative medical devices completed annually shall be given a one-time reward of up to 1 million yuan;
    , the biopharmaceutical industry is an important part of Zhuhai's modern industrial system.
    2019, the total output value of the city's biopharmaceutical industry was 25.19 billion yuan, an increase of 18.7% year-on-year.
    , there are 23 pharmaceutical manufacturing enterprises above the scale of Zhuhai City, 23 medical device enterprises, and 172 high-tech enterprises in the field of biomedicine and medical devices.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.